These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 32266676)

  • 1. A Δ
    Methaneethorn J; Poomsaidorn C; Naosang K; Kaewworasut P; Lohitnavy M
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):495-511. PubMed ID: 32266676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Physiologically-Based Pharmacokinetic Model of Δ
    Methaneethorn J; Naosang K; Kaewworasut P; Poomsaidorn C; Lohitnavy M
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):487-494. PubMed ID: 32253721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Verification of a Linked
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
    Wolowich WR; Greif R; Kleine-Brueggeney M; Bernhard W; Theiler L
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):691-711. PubMed ID: 31114948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans.
    Naef M; Russmann S; Petersen-Felix S; Brenneisen R
    J Pharm Sci; 2004 May; 93(5):1176-84. PubMed ID: 15067694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.
    Heuberger JA; Guan Z; Oyetayo OO; Klumpers L; Morrison PD; Beumer TL; van Gerven JM; Cohen AF; Freijer J
    Clin Pharmacokinet; 2015 Feb; 54(2):209-19. PubMed ID: 25316574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
    Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
    Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.
    Laplanche R; Meno-Tetang GM; Kawai R
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):373-400. PubMed ID: 17431753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis.
    Joerger M; Wilkins J; Fagagnini S; Baldinger R; Brenneisen R; Schneider U; Goldman B; Weber M
    Drug Metab Lett; 2012 Jun; 6(2):102-8. PubMed ID: 22594565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
    Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.
    Manwell LA; Mallet PE
    Psychopharmacology (Berl); 2015 May; 232(9):1655-65. PubMed ID: 25395060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lasting effects of repeated ∆
    Nguyen JD; Creehan KM; Kerr TM; Taffe MA
    Br J Pharmacol; 2020 Jan; 177(1):188-203. PubMed ID: 31478558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents.
    Manwell LA; Ford B; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):112-9. PubMed ID: 24956154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro/in vivo correlation studies for transdermal delta 8-THC development.
    Valiveti S; Hammell DC; Earles DC; Stinchcomb AL
    J Pharm Sci; 2004 May; 93(5):1154-64. PubMed ID: 15067692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Physiologically Based Pharmacokinetic and Drug-Drug Interaction Model for the CB2 Agonist Lenabasum.
    Fu Q; Jones HM; Sun G; Atamas SP
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):513-525. PubMed ID: 34143391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
    Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
    Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and Δ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs.
    Schaefer N; Kettner M; Laschke MW; Schlote J; Ewald AH; Menger MD; Maurer HH; Schmidt PH
    Curr Neuropharmacol; 2017; 15(5):713-723. PubMed ID: 27834143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmortem redistribution of THC in the pig.
    Brunet B; Hauet T; Hébrard W; Papet Y; Mauco G; Mura P
    Int J Legal Med; 2010 Nov; 124(6):543-9. PubMed ID: 20052591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.
    Adelli GR; Bhagav P; Taskar P; Hingorani T; Pettaway S; Gul W; ElSohly MA; Repka MA; Majumdar S
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2167-2179. PubMed ID: 28399267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.